ST. LOUIS, Dec. 3, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform.…
Read MoreST. LOUIS, Nov. 13, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington…
Read MoreST. LOUIS, Nov. 1, 2018 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that abstracts showcasing the WUGEN platform were accepted for an…
Read MoreLeukemia, Cooper et al, February 2018
Read MoreBiol Blood Marrow Transplant, Wagner et al, March 2017
Read MoreScience Translational Medicine, Romee et al, September 2016
Read MoreBiol Blood Marrow Transplant, Leong et al, April 2014
Read MoreCopyright © 2026 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design